Loading
NASDAQHealthcareMedical - Healthcare Information Services
Latest quote
$2.60
+$0.06 · +2.36%
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Previous close
$2.60
+$0.06 · +2.36%
Regular session · ET · Market data may be delayed.
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Day range
Current $2.60
52-week range
Current $2.60
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
69
Undervalued
Sentiment
54
Mixed
Risk
69
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Day range
Current $2.60
52-week range
Current $2.60
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 75.73K USD | 45.72K USD | 75.4K USD | 60.44K USD | 60.29K USD |
| Cost of goods sold | 296.31K USD | 129.77K USD | 75.73K USD | 65.3K USD | 69.18K USD |
| Gross profit | −220.58K USD | −84.04K USD | −324 USD | −4.85K USD | −8.88K USD |
| Research and development | 1.03T USD | 888.77K USD | 873.34K USD | 1.07M USD | 787.85K USD |
| Selling, general, and administrative | 6.03T USD | 4.59M USD | 4M USD | 4.49M USD | 2.16M USD |
| Operating expenses | 6.83M USD | 5.43M USD | 4.88M USD | 5.56M USD | 2.94M USD |
| Interest income | 411.06K USD | 318 USD | 172 USD | 2.51K USD | — |
| Interest expense | — | 535.47K USD | 608.29K USD | 1.51M USD | 476.48K USD |
| Depreciation and amortization | 227.41K USD | 193.14K USD | 162.67K USD | 143.62K USD | 186.39K USD |
| Operating income | −7.05M USD | −5.51M USD | −4.88M USD | −5.56M USD | −2.95M USD |
| Net income | −7.23M USD | −6.99M USD | −4.91M USD | −7.07M USD | −4.95M USD |
Company facts updated Sep 14, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 28, 2025 | 1:27 | — | — |
Stock split | Jan 30, 2025 | 1:335 | — | — |
Stock split | Jan 4, 2024 | 1:16 | — | — |
Effective Mar 28, 2025
1:27
Effective Jan 30, 2025
1:335
Effective Jan 4, 2024
1:16
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
